Abstracts tagged "Ankylosing spondylitis (AS) and tumor necrosis factor (TNF)"

Abstract Number: 2616 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry
Handan Yarkan¹, Gerçek Can¹, Sedat Capar², Berrin Zengin¹, Gokce Kenar¹, Servet Akar³, Ediz Dalkiliç⁴, Soner Senel⁵, Suleyman Serdar Koca⁶, Abdurrahman Tufan⁷, Ayten Yazici⁸, Nevsun İnanç⁹, Hülya Ellidokuz¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Statistics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁵Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁶Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁷Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁸Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁹Rheumatology, Marmara University faculty of Medicine, İstanbul, Turkey, ¹⁰Statistics, Dokuz Eylül Üniversity Faculty of Medicine, IZMIR, Turkey, ¹¹Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Although there is good evidence that smoking has a dose-dependent impact on structural damage progression in ankylosing spondylitis (AS) the evidence is poor for its…
Abstract Number: 709 • 2016 ACR/ARHP Annual Meeting
Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study
Philip J Mease¹, Josef S. Smolen², Dafna D Gladman³, Joachim Sieper⁴, John Weinman⁵, Julia Sommer⁶, Pascal Nurwakagari⁷ and Maja Hojnik⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medical University of Vienna, Vienna, Austria, ³University of Toronto, Toronto, ON, Canada, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵King's College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Ljubljana, Slovenia
Background/Purpose: Adherence to systemic therapies, such as tumor necrosis factor inhibitors (TNFi’s), is affected by various factors and may be critical for optimal disease outcomes…
Abstract Number: 2890 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naïve Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
Dominique Baeten¹, Ricardo Blanco², Piet Geusens³, Joachim Sieper⁴, Tseng Jui-Cheng⁵, Ruvie Martin⁶, Brian Porter⁶ and Hanno Richards⁷, ¹Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Maastricht University, Maastricht, Netherlands, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Anti‒TNFs are the only biologics currently approved for ankylosing spondylitis (AS). There is a significant unmet need in those patients (pts) with an inadequate…
Abstract Number: 2230 • 2012 ACR/ARHP Annual Meeting
The Early Clinical Response of TNF-Alpha Blockers Is a Predictor of Metrology Outcome in Ankylosing Spondylitis
Eon Jeong Nam¹, Jung Soo Eun¹, Na Ri Kim¹, Jong Wan Kang¹, Churl Hyun Im¹ and Young Mo Kang², ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: TNF-a blocker is the only treatment that shows a significant effect on spinal inflammation and life quality of patients with ankylosing spondylitis (AS). However,…
Abstract Number: 585 • 2012 ACR/ARHP Annual Meeting
Relative Overexpression of Membrane-Bound Versus Soluble TNF in Human and Experimental Spondyloarthritis
Carmen Ambarus¹, Leonie M. van Duivenvoorde¹, Huriatul Masdar¹, Melissa N. van Tok², Paul P. Tak¹, Nataliya Yeremenko³ and Dominique L. Baeten³, ¹Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Macrophages and their pro-inflammatory cytokines, including TNF, are pivotal mediators of chronic synovitis in rheumatoid arthritis (RA) as well as spondyloarthritis (SpA). Despite similar…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].